Circulating tumor cell number predicts time to progression (TTP) in patients with heavily pretreated gynecological cancers treated with selinexor (SEL)

M. Crochiere, Ignace B. Vergote, B. Lund, H. Havsteen, Z Ujmajuridze, Els Van Nieuwenhuysen, C. Haslund, T. Juhler-Nottrup, M. Mau-Sorensen, P. Berteloot, Anne L Kranich, J. Meade, George Wright, E. Shacham, T Rashal, Jean-Richard Saint-Martin, S Shacham, M Kauffman, M. R. Mirza, Yosef Landesman

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Original languageEnglish
Article number886P
JournalAnnals of Oncology
Issue numberSuppl. 6
Publication statusPublished - 2016
Event41st ESMO Congress: From disease treatment to patient care - København, Denmark
Duration: 7 Oct 201611 Oct 2016
Conference number: 41


Conference41st ESMO Congress
Internet address

Bibliographical note

ISI Document Delivery No.: EK4QS Times Cited: 0 Cited Reference Count: 0 Crochiere, M. Vergote, I. B. Lund, B. Havsteen, H. Ujmajuridze, Z. Van Nieuwenhuysen, E. Haslund, C. Juhler-Nottrup, T. Mau-Sorensen, M. Berteloot, P. Kranich, A. Meade, J. Wright, G. Shacham, E. Rashal, T. Saint-Martin, J-R. Shacham, S. Kauffman, M. Mirza, M. Raza Landesman, Y. Karyopharm Therapeutics, Inc. 0 Oxford univ press Oxford 1569-8041 6


  • Oncology

Cite this